{"filing":{"accession_number":"0001575872-26-000520","cik":"0001135951","ticker":"RDY","company_name":"DR REDDYS LABORATORIES LTD","form":"6-K","filing_date":"2026-07-22","report_date":null,"primary_document":"rdy0925_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1135951/000157587226000520/rdy0925_6k.htm"},"events":[{"id":19430,"run_id":17489,"accession_number":"0001575872-26-000520","anchor_item_number":"EX-99.1","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"The Board approved on July 22, 2026, the appointment of Dr. Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel, with induction into the Management Council.","company_name":"DR REDDYS LABORATORIES LTD","ticker":"RDY","filing_date":"2026-07-22","form":"6-K","submitted_at":null,"items":[{"id":18515,"accession_number":"0001575872-26-000520","item_number":"EX-99.1","item_title":"rdy0925_ex99-1.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The exhibit discloses the Board's approval on July 22, 2026, of Dr. Sridevi Khambhampaty's appointment as Global Head of Biologics and Senior Management Personnel, with induction into the Management Council. While the exhibit also covers quarterly financial results and auditor appointment, the principal discrete event disclosed is the executive appointment. The appointment is material as it involves a senior leadership role in a key business segment (Biologics) at a major pharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-22T17:37:51.949667+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":19431,"run_id":17489,"accession_number":"0001575872-26-000520","anchor_item_number":"EX-99.2","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Dr. Reddy's announced consolidated financial results for Q1FY27 (quarter ended June 30, 2026), reporting revenues of ₹80.7 billion, EBITDA of ₹10.1 billion, and profit after tax of ₹4.4 billion, with a material ₹2.4 billion provision related to semaglutide API issues reducing margins by approximately 3%.","company_name":"DR REDDYS LABORATORIES LTD","ticker":"RDY","filing_date":"2026-07-22","form":"6-K","submitted_at":null,"items":[{"id":18516,"accession_number":"0001575872-26-000520","item_number":"EX-99.2","item_title":"rdy0925_ex99-2.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a press release announcing Dr. Reddy's consolidated financial results for Q1FY27 (quarter ended June 30, 2026), disclosing revenues of ₹80.7 billion, EBITDA of ₹10.1 billion, and profit after tax of ₹4.4 billion. The document explicitly states \"Dr. Reddy's Q1FY27 Financial Results\" and presents detailed income statement, balance sheet, and cash flow metrics. Material to investors as it reports quarterly earnings and highlights a significant ₹2.4 billion provision related to semaglutide API issues that reduced margins by ~3%.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-22T17:37:51.949667+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":18515,"accession_number":"0001575872-26-000520","item_number":"EX-99.1","item_title":"rdy0925_ex99-1.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The exhibit discloses the Board's approval on July 22, 2026, of Dr. Sridevi Khambhampaty's appointment as Global Head of Biologics and Senior Management Personnel, with induction into the Management Council. While the exhibit also covers quarterly financial results and auditor appointment, the principal discrete event disclosed is the executive appointment. The appointment is material as it involves a senior leadership role in a key business segment (Biologics) at a major pharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-22T17:37:51.949667+00:00","company_name":"DR REDDYS LABORATORIES LTD","ticker":"RDY","filing_date":"2026-07-22"},{"id":18516,"accession_number":"0001575872-26-000520","item_number":"EX-99.2","item_title":"rdy0925_ex99-2.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a press release announcing Dr. Reddy's consolidated financial results for Q1FY27 (quarter ended June 30, 2026), disclosing revenues of ₹80.7 billion, EBITDA of ₹10.1 billion, and profit after tax of ₹4.4 billion. The document explicitly states \"Dr. Reddy's Q1FY27 Financial Results\" and presents detailed income statement, balance sheet, and cash flow metrics. Material to investors as it reports quarterly earnings and highlights a significant ₹2.4 billion provision related to semaglutide API issues that reduced margins by ~3%.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-22T17:37:51.949667+00:00","company_name":"DR REDDYS LABORATORIES LTD","ticker":"RDY","filing_date":"2026-07-22"},{"id":18517,"accession_number":"0001575872-26-000520","item_number":"EX-99.3","item_title":"rdy0925_ex99-3.htm","event_type":"periodic_quarterly","event_domain":"periodic","is_material":true,"confidence":0.95,"reasoning":"This exhibit presents unaudited consolidated financial results for the quarter ended 30 June 2026, prepared in accordance with IFRS and presented per SEBI Regulation 33 format. It is a periodic quarterly financial report (the foreign-issuer equivalent of a 10-Q), not a discrete earnings-release event. The document includes segment information, detailed notes on material items (Semaglutide provision, CAR-T impairment, Immutep investment loss, VAT provision), and was approved by the Board on 22 July 2026. As a periodic financial report itself rather than a press release announcing results, it should be classified as periodic_quarterly and deferred for separate processing.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-22T17:37:51.949667+00:00","company_name":"DR REDDYS LABORATORIES LTD","ticker":"RDY","filing_date":"2026-07-22"},{"id":18518,"accession_number":"0001575872-26-000520","item_number":"EX-99.4","item_title":"rdy0925_ex99-4.htm","event_type":"periodic_quarterly","event_domain":"periodic","is_material":false,"confidence":0.95,"reasoning":"This exhibit is an independent auditor's review report and accompanying unaudited consolidated financial results statement for the quarter ended June 30, 2026, prepared pursuant to Regulation 33 of the SEBI Listing Regulations. It is a periodic quarterly financial report (the foreign-issuer equivalent of a 10-Q), not a discrete event or earnings release press announcement. The document itself is the financial report being furnished, not a news release announcing results.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-22T17:37:51.949667+00:00","company_name":"DR REDDYS LABORATORIES LTD","ticker":"RDY","filing_date":"2026-07-22"},{"id":18519,"accession_number":"0001575872-26-000520","item_number":"EX-99.5","item_title":"rdy0925_ex99-5.htm","event_type":"periodic_quarterly","event_domain":"periodic","is_material":false,"confidence":0.95,"reasoning":"This exhibit is an Independent Auditor's Review Report on unaudited standalone financial results for the quarter ended 30 June 2026, prepared pursuant to Regulation 33 of the SEBI Listing Regulations. The document presents a complete quarterly financial statement with revenue, expenses, profit/loss, and earnings per share, along with segment information. This is a periodic quarterly financial report itself (the foreign-issuer equivalent of a 10-Q), not a discrete event or earnings press release announcing results.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-22T17:37:51.949667+00:00","company_name":"DR REDDYS LABORATORIES LTD","ticker":"RDY","filing_date":"2026-07-22"}]}